RegeneRx Biopharmaceuticals Inc. (“RegeneRx” or the “Company”) (OTCQB:RGRX) is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. We have formulated Tß4 into three distinct product candidates in clinical development:
Company profile
Ticker
RGRX
Exchange
Website
CEO
J. J. Finkelstein
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ALPHA 1 BIOMEDICALS INC, ALPHA 1 BIOMEDICALS INC /DE/
SEC CIK
Corporate docs
IRS number
521253406
RGRX stock data
Investment data
Securities sold
Number of investors
Calendar
12 Aug 22
19 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 706.65K | 706.65K | 706.65K | 706.65K | 706.65K | 706.65K |
| Cash burn (monthly) | 72.89K | 109.91K | 181.99K | 154.12K | 72.89K | 26.04K |
| Cash used (since last report) | 122.51K | 184.74K | 305.9K | 259.06K | 122.51K | 43.76K |
| Cash remaining | 584.14K | 521.91K | 400.75K | 447.59K | 584.14K | 662.88K |
| Runway (months of cash) | 8.0 | 4.7 | 2.2 | 2.9 | 8.0 | 25.5 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 May 22 | Mcnay Joseph C | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 290,000 | 55.1K | 290,000 |
| 17 May 22 | Finkelstein J J | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 600,000 | 114K | 600,000 |
| 17 May 22 | Elsey R Don | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 290,000 | 55.1K | 290,000 |
| 17 May 22 | Noseda Alessandro | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 240,000 | 45.6K | 240,000 |
| 17 May 22 | Bove Mauro | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 240,000 | 45.6K | 240,000 |
Institutional ownership, Q1 2022
35.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 13.96M |
| Total shares | 51.53M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Essetifin SPA | 51.52M | $13.96M |
| Williams Jones Wealth Management | 10K | $2K |
Financial report summary
?Competition
Kala PharmaceuticalsManagement Discussion
- Revenues. For the three months ended June 30, 2022 and 2021, we recorded revenue in the amount of approximately $19,000 related to the amortization of unearned license fees.
- R&D Expenses. We did not record any R&D expenses for the three months ended June 30, 2022. Our R&D expenses were approximately $500 for the same period in 2021. The reduction of our R&D expenses over the past several years reflects the shift in our business resulting from our partnering strategy.
- G&A Expenses. For the three months ended June 30, 2022, our G&A expenses increased by approximately $208,000, or 75%, to $484,000 from $276,000 for the same period in 2021. The changes in the G&A expenses are reflected in several areas. Increases in stock option expense (increase of $190,000), professional services (increase of $14,000), investor relations (increase of $7,000) facility related (increase of $2,000) and insurance (increase of $3,000) were offset by a decrease in personnel related (decrease of $8,000). We expect that our G&A expenses will remain steady over the next year.
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
agreed, binding, CRO, death, deteriorating, economy, inflammatory, light, PIPE, respiratory, Russia, septic, shock, therapy, worsening
Removed:
awaiting, confirmation, discussing, improve, keratopathy, neurovascular, official, partnership, prospective, rare, talking
Financial reports
Current reports
8-K
2021 Annual Stockholders Meeting
15 Nov 21
8-K
Regulation FD Disclosure
22 Jul 21
8-K
Entry into a Material Definitive Agreement
1 Jul 21
8-K
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
14 May 21
8-K
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
19 Mar 21
8-K
Entry into a Material Definitive Agreement
21 Oct 20
8-K
RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome
13 Oct 20
8-K
Submission of Matters to a Vote of Security Holders
30 Sep 19
8-K
Entry into a Material Definitive Agreement
5 Mar 19
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 18
Registration and prospectus
424B3
Prospectus supplement
17 Nov 21
S-1/A
IPO registration (amended)
2 Sep 21
S-1
IPO registration
17 Aug 21
424B3
Prospectus supplement
17 Aug 20
424B3
Prospectus supplement
17 Aug 20
424B3
Prospectus supplement
30 Mar 20
424B3
Prospectus supplement
30 Mar 20
424B3
Prospectus supplement
18 Nov 19
424B3
Prospectus supplement
18 Nov 19
424B3
Prospectus supplement
15 Aug 19
Other
EFFECT
Notice of effectiveness
7 Sep 21
CORRESP
Correspondence with SEC
2 Sep 21
UPLOAD
Letter from SEC
18 Aug 21
EFFECT
Notice of effectiveness
24 Oct 18
CORRESP
Correspondence with SEC
21 Oct 18
UPLOAD
Letter from SEC
17 Oct 18
CT ORDER
Confidential treatment order
11 Dec 17
EFFECT
Notice of effectiveness
2 Aug 16
CORRESP
Correspondence with SEC
1 Aug 16
UPLOAD
Letter from SEC
24 Jul 16
Ownership
4
REGENERX BIOPHARMACEUTICALS / ALLAN L GOLDSTEIN ownership change
19 May 22
4
REGENERX BIOPHARMACEUTICALS / Mauro Bove ownership change
19 May 22
4
REGENERX BIOPHARMACEUTICALS / Alessandro Noseda ownership change
19 May 22
4
REGENERX BIOPHARMACEUTICALS / R Don Elsey ownership change
19 May 22
4
REGENERX BIOPHARMACEUTICALS / JOSEPH C MCNAY ownership change
19 May 22
4
REGENERX BIOPHARMACEUTICALS / J J FINKELSTEIN ownership change
19 May 22
4
REGENERX BIOPHARMACEUTICALS / ALLAN L GOLDSTEIN ownership change
2 Mar 22
4
REGENERX BIOPHARMACEUTICALS / JOSEPH C MCNAY ownership change
4 Aug 21
4
REGENERX BIOPHARMACEUTICALS / ALLAN L GOLDSTEIN ownership change
4 Aug 21
4
REGENERX BIOPHARMACEUTICALS / R Don Elsey ownership change
4 Aug 21